Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728504 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
A Phase 2 study, sponsored by Asana BioSciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT03728504 is a Phase 2 study that has completed, run by Asana BioSciences. The registered enrollment target is 97 participants.
The verdict
NCT03728504, a Phase 2 study, has completed, sponsored by Asana BioSciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
Interventions
- DRUG Placebo Oral Tablet
- DRUG ASN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728504
The ClinicalTrials.gov registry entry for NCT03728504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03728504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03728504 about?
NCT03728504 is a clinical study titled "Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema". Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.
What is the current status of trial NCT03728504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2019-01-03. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT03728504?
The interventions under investigation include: Placebo Oral Tablet (DRUG), ASN002 (DRUG).
Who is sponsoring clinical trial NCT03728504?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.